secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001193125-23-270377
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics reports favorable Phase 1/2 data for SNS-101 at SITC 2023
--------------------------------------------------------------------------------

- SNS-101 dose escalation (13 patients): well-tolerated, no DLTs, no CRS; only one related AE (Grade 2 dermatitis).
- Pharmacokinetics: dose-proportional exposure, linear elimination, no target-mediated drug disposition; supports every-three-week dosing.
- SNS-101 achieved dose levels >10x higher than a competitor VISTA antibody that was halted due to CRS, suggesting best-in-class potential.
- Expected data readouts: initial combo safety/PK data Q1 2024, topline monotherapy Q2 2024, topline combo later in 2024.
- Late-breaking poster at SITC 2023 on Nov 4; data supports conditionally active VISTA-blocking approach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312523270377/0001193125-23-270377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312523270377/d556062d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-270377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer